Same sparkle, different story: how lab-grown diamonds are transforming the market 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
CHESTERBROOK, Pa., May 02, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Deutsche Bank 43rd Annual Healthcare Conference on Tuesday, May 8th, 2018, at 3:30 p.m. EDT in Boston, MA.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
